tiprankstipranks
Zealand Pharma (ZLDPF)
OTHER OTC:ZLDPF
US Market
ZLDPF
Zealand Pharma
RESEARCH TOOLSreports
Want to see ZLDPF full AI Analyst Report?

Zealand Pharma (ZLDPF) Stock Forecast & Price Target

195 Followers
See the Price Targets and Ratings of:

ZLDPF Analyst Ratings

Moderate Buy
11Ratings
Moderate Buy
6 Buy
5 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Zealand
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ZLDPF Stock 12 Month Forecast

Average Price Target

$77.03
▲(50.06% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Zealand Pharma in the last 3 months. The average price target is $77.03 with a high forecast of $128.05 and a low forecast of $42.68. The average price target represents a 50.06% change from the last price of $51.33.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"41":"$41","63":"$63","85":"$85","107":"$107","129":"$129"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":128.05485,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$128.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":77.0269325,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$77.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.68495,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$42.68</span>\n  </div></div>","useHTML":true}}],"tickPositions":[41,63,85,107,129],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.37,53.57652692307692,59.78305384615384,65.98958076923077,72.19610769230769,78.40263461538461,84.60916153846154,90.81568846153846,97.02221538461538,103.2287423076923,109.43526923076922,115.64179615384614,121.84832307692307,{"y":128.05485,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.37,49.6513025,51.932604999999995,54.2139075,56.49521,58.776512499999995,61.057815,63.3391175,65.62042,67.9017225,70.183025,72.4643275,74.74563,{"y":77.0269325,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.37,47.009611538461535,46.64922307692307,46.288834615384616,45.92844615384615,45.56805769230769,45.20766923076923,44.84728076923077,44.48689230769231,44.126503846153845,43.76611538461538,43.40572692307693,43.04533846153846,{"y":42.68495,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":70.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.47,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.75,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.88,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.79,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.15,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.88,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.14,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.33,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.635,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.37,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$128.05Average Price Target$77.03Lowest Price Target$42.68
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on ZLDPF
Yihan Li
Barclays
Barclays
$65.97
Buy
28.52%
Upside
Reiterated
05/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
UBS Analyst forecast on ZLDPF
Xian Deng
UBS
UBS
$113.31
Buy
120.75%
Upside
Reiterated
05/08/26
UBS Remains a Buy on Zealand Pharma (ZLDPF)
SEB Enskilda Analyst forecast on ZLDPF
Thomas Bowers
SEB Enskilda
SEB Enskilda
$58.98→$73.73
Buy
43.64%
Upside
Upgraded
04/29/26
Zealand Pharma upgraded to Buy from Hold at SEB EquitiesZealand Pharma upgraded to Buy from Hold at SEB Equities
Jefferies Analyst forecast on ZLDPF
Benjamin Jackson CFA
Jefferies
Jefferies
$78.39
Buy
52.71%
Upside
Reiterated
04/19/26
Zealand Pharma (ZLDPF) Receives a Buy from Jefferies
Deutsche Bank Analyst forecast on ZLDPF
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
$69.85→$42.68
Hold
-16.84%
Downside
Reiterated
03/12/26
Zealand Pharma price target lowered to DKK 275 from DKK 450 at Deutsche BankZealand Pharma price target lowered to DKK 275 from DKK 450 at Deutsche Bank
J.P. Morgan Analyst forecast on ZLDPF
James Gordon
J.P. Morgan
J.P. Morgan
$155.22→$71.4
Buy
39.10%
Upside
Reiterated
03/11/26
Zealand Pharma price target lowered to DKK 460 from DKK 1,000 at JPMorganZealand Pharma price target lowered to DKK 460 from DKK 1,000 at JPMorgan
Berenberg Bank Analyst forecast on ZLDPF
Unknown Analyst
Berenberg Bank
Not Ranked
Berenberg Bank
$128.05
Buy
149.47%
Upside
Reiterated
03/06/26
Zealand Pharma (ZLDPF) Receives a Buy from Berenberg Bank
William Blair Analyst forecast on ZLDPF
Andy Hsieh
William Blair
William Blair
―
Hold
―
Downgraded
03/06/26
Zealand Pharma downgraded to Market Perform from Outperform at William BlairZealand Pharma downgraded to Market Perform from Outperform at William Blair
Cantor Fitzgerald Analyst forecast on ZLDPF
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Hold
―
Downgraded
03/06/26
Zealand Pharma downgraded to Neutral from Overweight at Cantor FitzgeraldZealand Pharma downgraded to Neutral from Overweight at Cantor Fitzgerald
Exane BNP Paribas Analyst forecast on ZLDPF
Kirsty Ross Stewart
Exane BNP Paribas
Exane BNP Paribas
$42.68
Hold
-16.84%
Downside
Downgraded
03/06/26
Zealand Pharma downgraded to Neutral from Outperform at BNP ParibasZealand Pharma downgraded to Neutral from Outperform at BNP Paribas
Nordea Markets Analyst forecast on ZLDPF
Martin Brenoe
Nordea Markets
Nordea Markets
―
Hold
―
Downgraded
03/06/26
Zealand Pharma downgraded to Hold from Buy at NordeaZealand Pharma downgraded to Hold from Buy at Nordea
Wells Fargo Analyst forecast on ZLDPF
Cerena Chen
Wells Fargo
Wells Fargo
$100.89
Buy
96.56%
Upside
Initiated
07/24/25
Zealand Pharma initiated with an Overweight at Wells FargoZealand Pharma initiated with an Overweight at Wells Fargo
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on ZLDPF
Yihan Li
Barclays
Barclays
$65.97
Buy
28.52%
Upside
Reiterated
05/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
UBS Analyst forecast on ZLDPF
Xian Deng
UBS
UBS
$113.31
Buy
120.75%
Upside
Reiterated
05/08/26
UBS Remains a Buy on Zealand Pharma (ZLDPF)
SEB Enskilda Analyst forecast on ZLDPF
Thomas Bowers
SEB Enskilda
SEB Enskilda
$58.98→$73.73
Buy
43.64%
Upside
Upgraded
04/29/26
Zealand Pharma upgraded to Buy from Hold at SEB EquitiesZealand Pharma upgraded to Buy from Hold at SEB Equities
Jefferies Analyst forecast on ZLDPF
Benjamin Jackson CFA
Jefferies
Jefferies
$78.39
Buy
52.71%
Upside
Reiterated
04/19/26
Zealand Pharma (ZLDPF) Receives a Buy from Jefferies
Deutsche Bank Analyst forecast on ZLDPF
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
$69.85→$42.68
Hold
-16.84%
Downside
Reiterated
03/12/26
Zealand Pharma price target lowered to DKK 275 from DKK 450 at Deutsche BankZealand Pharma price target lowered to DKK 275 from DKK 450 at Deutsche Bank
J.P. Morgan Analyst forecast on ZLDPF
James Gordon
J.P. Morgan
J.P. Morgan
$155.22→$71.4
Buy
39.10%
Upside
Reiterated
03/11/26
Zealand Pharma price target lowered to DKK 460 from DKK 1,000 at JPMorganZealand Pharma price target lowered to DKK 460 from DKK 1,000 at JPMorgan
Berenberg Bank Analyst forecast on ZLDPF
Unknown Analyst
Berenberg Bank
Not Ranked
Berenberg Bank
$128.05
Buy
149.47%
Upside
Reiterated
03/06/26
Zealand Pharma (ZLDPF) Receives a Buy from Berenberg Bank
William Blair Analyst forecast on ZLDPF
Andy Hsieh
William Blair
William Blair
―
Hold
―
Downgraded
03/06/26
Zealand Pharma downgraded to Market Perform from Outperform at William BlairZealand Pharma downgraded to Market Perform from Outperform at William Blair
Cantor Fitzgerald Analyst forecast on ZLDPF
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Hold
―
Downgraded
03/06/26
Zealand Pharma downgraded to Neutral from Overweight at Cantor FitzgeraldZealand Pharma downgraded to Neutral from Overweight at Cantor Fitzgerald
Exane BNP Paribas Analyst forecast on ZLDPF
Kirsty Ross Stewart
Exane BNP Paribas
Exane BNP Paribas
$42.68
Hold
-16.84%
Downside
Downgraded
03/06/26
Zealand Pharma downgraded to Neutral from Outperform at BNP ParibasZealand Pharma downgraded to Neutral from Outperform at BNP Paribas
Nordea Markets Analyst forecast on ZLDPF
Martin Brenoe
Nordea Markets
Nordea Markets
―
Hold
―
Downgraded
03/06/26
Zealand Pharma downgraded to Hold from Buy at NordeaZealand Pharma downgraded to Hold from Buy at Nordea
Wells Fargo Analyst forecast on ZLDPF
Cerena Chen
Wells Fargo
Wells Fargo
$100.89
Buy
96.56%
Upside
Initiated
07/24/25
Zealand Pharma initiated with an Overweight at Wells FargoZealand Pharma initiated with an Overweight at Wells Fargo
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zealand Pharma

3 Months
James GordonJ.P. Morgan
Success Rate
2/5 ratings generated profit
40%
Average Return
-10.80%
Copying James Gordon's trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of -10.80% per trade.
1 Year
James GordonJ.P. Morgan
Success Rate
1/5 ratings generated profit
20%
Average Return
-24.86%
Copying James Gordon's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -24.86% per trade.
2 Years
James GordonJ.P. Morgan
Success Rate
1/5 ratings generated profit
20%
Average Return
-33.36%
Copying James Gordon's trades and holding each position for 2 Years would result in 20.00% of your transactions generating a profit, with an average return of -33.36% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZLDPF Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
4
4
4
5
6
Buy
0
0
0
0
1
Hold
1
1
6
6
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
5
10
11
13
In the current month, ZLDPF has received 7 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. ZLDPF average Analyst price target in the past 3 months is 77.03.
Each month's total comprises the sum of three months' worth of ratings.

ZLDPF Financial Forecast

ZLDPF Earnings Forecast

Next quarter’s earnings estimate for ZLDPF is $0.15 with a range of -$0.13 to $0.56. The previous quarter’s EPS was -$0.87. ZLDPF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ZLDPF has Performed in-line its overall industry.
Next quarter’s earnings estimate for ZLDPF is $0.15 with a range of -$0.13 to $0.56. The previous quarter’s EPS was -$0.87. ZLDPF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ZLDPF has Performed in-line its overall industry.

ZLDPF Sales Forecast

Next quarter’s sales forecast for ZLDPF is $128.50M with a range of $115.44M to $151.50M. The previous quarter’s sales results were $5.30M. ZLDPF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ZLDPF has Performed in-line its overall industry.
Next quarter’s sales forecast for ZLDPF is $128.50M with a range of $115.44M to $151.50M. The previous quarter’s sales results were $5.30M. ZLDPF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ZLDPF has Performed in-line its overall industry.

ZLDPF Stock Forecast FAQ

What is ZLDPF’s average 12-month price target, according to analysts?
Based on analyst ratings, Zealand Pharma’s 12-month average price target is 77.03.
    What is ZLDPF’s upside potential, based on the analysts’ average price target?
    Zealand Pharma has 50.06% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ZLDPF a Buy, Sell or Hold?
          Zealand Pharma has a consensus rating of Moderate Buy which is based on 6 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Zealand Pharma’s price target?
            The average price target for Zealand Pharma is 77.03. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $128.05 ,the lowest forecast is $42.68. The average price target represents 50.06% Increase from the current price of $51.33.
              What do analysts say about Zealand Pharma?
              Zealand Pharma’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of ZLDPF?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.